US 12,012,412 B2
Solid forms of pyrazolo[3,4-d]pyrimidine compounds
Caroline Yvette Proulx-Lafrance, Natick, MA (US); John C. Amedio, Jr., Burlington, MA (US); and Erika Volckova, Concord, MA (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Dec. 16, 2022, as Appl. No. 18/082,622.
Claims priority of provisional application 63/290,136, filed on Dec. 16, 2021.
Prior Publication US 2023/0192707 A1, Jun. 22, 2023
Int. Cl. C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [C07B 2200/13 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A solid form of Compound X:

OG Complex Work Unit Chemistry
wherein the solid form is selected from:
Form A: characterized by having X-ray powder diffraction peaks at approximately 18.9, 20.4, and 23.1° 2θ using Cu Kα radiation,
Form B: characterized by having X-ray powder diffraction peaks at approximately 8.0, 15.0, and 19.3° 2θ using Cu Kα radiation,
Form C: characterized by having X-ray powder diffraction peaks at approximately 15.0, 18.9, and 24.7° 2θ using Cu Kα radiation, and
Form D: characterized by having X-ray powder diffraction peaks at approximately 6.8, 9.1, and 15.5° 2θ using Cu Kα radiation.